Literature DB >> 25541253

Structures and binding studies of the complexes of phospholipase A2 with five inhibitors.

Prakash Kumar Shukla1, Lovely Gautam1, Mau Sinha1, Punit Kaur1, Sujata Sharma1, Tej P Singh2.   

Abstract

Phospholipase A2 (PLA2) catalyzes the hydrolysis of phospholipids into arachidonic acid and lysophospholipids. Arachidonic acid is used as a substrate in the next step of the multistep pathway leading to the production of eicosanoids. The eicosanoids, in extremely low concentrations, are required in a number of physiological processes. However, the increase in their concentrations above the essential physiological requirements leads to various inflammatory conditions. In order to prevent the unwanted rise in the concentrations of eicosanoids, the actions of PLA2 and other enzymes of the pathway need to be blocked. We report here the structures of five complexes of group IIA PLA2 from Daboia russelli pulchella with tightly binding inhibitors, (i) p-coumaric acid, (ii) resveratrol, (iii) spermidine, (iv) corticosterone and (v) gramine derivative. The binding studies using fluorescence spectroscopy and surface plasmon resonance techniques for the interactions of PLA2 with the above five compounds showed high binding affinities with values of dissociation constants (KD) ranging from 3.7×10(-8) M to 2.1×10(-9) M. The structure determinations of the complexes of PLA2 with the above five compounds showed that all the compounds bound to PLA2 in the substrate binding cleft. The protein residues that contributed to the interactions with these compounds included Leu2, Leu3, Phe5, Gly6, Ile9, Ala18, Ile19, Trp22, Ser23, Cys29, Gly30, Cys45, His48, Asp49 and Phe106. The positions of side chains of several residues including Leu2, Leu3, Ile19, Trp31, Lys69, Ser70 and Arg72 got significantly shifted while the positions of active site residues, His48, Asp49, Tyr52 and Asp99 were unperturbed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Binding study; Crystal structure; Inflammation; Inhibitor; Phospholipase A2

Mesh:

Substances:

Year:  2014        PMID: 25541253     DOI: 10.1016/j.bbapap.2014.12.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  Plant-Derived Toxin Inhibitors as Potential Candidates to Complement Antivenom Treatment in Snakebite Envenomations.

Authors:  Asenate A X Adrião; Aline O Dos Santos; Emilly J S P de Lima; Jéssica B Maciel; Weider H P Paz; Felipe M A da Silva; Manuela B Pucca; Ana M Moura-da-Silva; Wuelton M Monteiro; Marco A Sartim; Hector H F Koolen
Journal:  Front Immunol       Date:  2022-05-09       Impact factor: 8.786

2.  A novel GPR55-mediated satiety signal in the oval Bed Nucleus of the Stria Terminalis.

Authors:  E R Hawken; C P Normandeau; J Gardner Gregory; B Cécyre; J-F Bouchard; K Mackie; É C Dumont
Journal:  Neuropsychopharmacology       Date:  2019-01-07       Impact factor: 7.853

Review 3.  Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy?

Authors:  Sabine Weiskirchen; Ralf Weiskirchen
Journal:  Adv Nutr       Date:  2016-07-15       Impact factor: 8.701

Review 4.  Polypharmacology or Promiscuity? Structural Interactions of Resveratrol With Its Bandwagon of Targets.

Authors:  Uzma Saqib; Tanya T Kelley; Siva K Panguluri; Dongfang Liu; Rajkumar Savai; Mirza S Baig; Stephan C Schürer
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

Review 5.  Perspective on the Therapeutics of Anti-Snake Venom.

Authors:  Isabel Gómez-Betancur; Vedanjali Gogineni; Andrea Salazar-Ospina; Francisco León
Journal:  Molecules       Date:  2019-09-09       Impact factor: 4.411

6.  Anti-5'-Nucleotidases (5'-ND) and Acetylcholinesterase (AChE) Activities of Medicinal Plants to Combat Echis carinatus Venom-Induced Toxicities.

Authors:  Nazia Aslam; Syeda Fatima; Sofia Khalid; Shahzad Hussain; Mughal Qayum; Khurram Afzal; Muhammad Hassham Hassan Bin Asad
Journal:  Biomed Res Int       Date:  2021-02-04       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.